Columbia University

Technology Ventures

Featured Funding Opportunities

In support of its mission to facilitate the transfer of inventions from academic research labs to the market, CTV publicizes funding opportunities that may be relevant to Columbia inventors as they conduct research and develop new technologies. For additional lists of funding opportunities, refer to these resources:

For further assistance with grant applications, see CTV's collection of IP and Entrepreneurship Language for Grant Applications.

Upcoming Opportunities

right
Deadline: 
Monday, December 5, 2022 - 5:00pm

S2S is an invitation-only symposium for top scientists from leading research institutions to present their startup ideas and interact with leading investors and executives in the Boston biotechnology hub. 200+ anticipated attendees include entrepreneurs, biotech investors (Angels / VCs), pharma scouts, academic investigators, TTOs, etc. The symposium is a setting to showcase research from selected scientists. Submissions are reviewed by a senior Advisory Group. TTOs are also encouraged to submit 1-page proposals on behalf of researchers.

Past Funding Opportunities

right
Deadline: 
Thursday, October 6, 2022 - 5:00pm

Governor Hochul Announces Applications Open for Second Round of New York’s $40 Million Biodefense Commercialization Fund (Applications and Fund Guidelines Available 

right
Deadline: 
Monday, May 30, 2022 - 5:00pm

Chiesi Global Rare Diseases is seeking research proposals for new technologies from academic medical centers, universities, and research institutions globally for technologies to address distribution of macromolecules in hard-to-reach tissues

Pre-Proposal Deadline: May 30, 2022. Please reach out to your CTV licensing officer before submitting a pre-proposal.

right
Deadline: 
Wednesday, April 6, 2022 - 5:00pm

Pfizer is seeking proposals for the advancement of RNA therapeutics and the development of the next generation of RNA medicines.

Deadline to submit to [email protected]: April 6, 2022

Submissions invited for novel target concepts and therapeutic strategies amenable to RNA based approaches (mRNA, circular RNA, gene editing), in the following areas of interest:

right
Deadline: 
Monday, November 22, 2021 - 5:00pm

 

 

Overview:

The 'Math Meets Bio’ Columbia-AlleyCorp Collaboration aims to accelerate the transition of innovative technologies for the lab to market and stimulate start-up activity to support the New York Life Science-Tech ecosystem at the intersection of mathematics and biology.

Pre-Proposals must be submitted by November 22, 2021 at 5:00PM ET

right
Deadline: 
Monday, November 22, 2021 - 5:00pm

The RTW Charitable Foundation Accelerator, administered by Columbia Technology Ventures, is a strategic research alliance between the RTW Charitable Foundation and select New York-based academic institutions, to accelerate translational research in the field of rare diseases with particular interest in ultra-rare and underfunded rare diseases.

right
Deadline: 
Friday, October 15, 2021 - 5:00pm

BioMarin is a world leader in developing and commercializing first-in-class and best-in-class innovative biopharmaceuticals for rare diseases driven by genetic causes. BioMarin’s mission is to bring new treatments to market that will make a big impact on small patient populations. We are inviting scientists to submit short proposals to join our efforts in advancing treatments for rare diseases.

Focus Area

right
Deadline: 
Monday, October 4, 2021 - 5:00pm

Applications are now available for New York State’s new $40 million Biodefense Commercialization Fund that will provide grants of as much as $4 million to startups and academic research projects to help accelerate the development and commercialization of life science research that addresses serious infectious disease threats, including COVID-19 and its variants.

right
Deadline: 
Wednesday, June 30, 2021 - 10:00am

aMoon Velocity is aMoon’s early-stage investment fund. Our investments target disruptive, cutting-edge technologies and range from sponsored research at top academic and clinical institutions, to venture formation through seed investments. We don’t define ourselves by vertical, need, or even geographical boundaries but by our passion for partnering with entrepreneurs and scientists developing new solutions to major healthcare challenges.

Pages